Epidermal growth factor receptor (EGFR) amplification and type III mutation (EGFRvIII), associated with constitutive tyrosine kinase activation and high malignancy, are commonly observed in glioblastoma tumors. The association of EGFR and EGFRvIII with caveolins was investigated in human glioblastoma cell lines, U87MG and U87MG-EGFRvIII. Caveolin-1 expression, determined by RT-PCR, real-time quantitative PCR and Western blot, was upregulated in glioblastoma cell lines (two-fold) and tumors (20-300-fold) compared to primary human astrocytes and nonmalignant brain tissue, respectively. U87MG-EGFRvIII expressed higher levels of caveolin-1 than U87MG. In contrast, the expression of caveolin-2 and -3 were downregulated in glioblastoma cells compared to astrocytes. A colocalization of EGFR, but not of EGFRvIII, with lipid rafts and caveolin-1 was observed by immunocytochemistry. Association of EGFR and EGFRvIII with caveolae, assessed in vitro by binding to caveolin scaffolding domain peptides and in vivo by immunocolocalization studies in cells and caveolae-enriched cellular fraction, was phosphorylation-dependent: ligand-induced phosphorylation of EGFR resulted in dissociation of EGFR from caveolae. In contrast, inhibition of the EGFRvIII constitutive tyrosine phosphorylation by AG1478 increased association of EGFRvIII with caveolin-1. AG1478 also increased caveolin-1 expression and reduced glioblastoma cell growth in a semi-solid agar. The evidence suggests that the phosphorylation-regulated sequestration of EGFR in caveolae may be involved in arresting constitutive or ligand-induced signaling through EGFR responsible for glial cell transformation.
Introduction
Glioblastoma multiforme (GBM) is the most aggressive primary brain tumor characterized by anaplastic, infiltrative and angiogenic properties (Kleihues and Ohgaki, 1999) . The epidermal growth factor receptor (EGFR) gene is amplified in 40% of glioblastomas and often displays various genomic rearrangements (Nishikawa et al., 1994; Kleihues and Ohgaki, 1999) . The most common rearrangement of the EGFR gene is type III mutation, an in-frame deletion of 801 bp, spanning mRNA exons 2-7 (Nishikawa et al., 1994) . Type III mutation of EGFR (EGFRvIII) results in the expression of a truncated receptor that shows constitutive tyrosine kinase activity (Voldborg et al., 1997) and aberrant receptor signaling (Nagane et al., 2001) . Glioblastoma cells expressing EGFRvIII exhibit increased proliferation, reduced apoptotic rates, and higher malignancy (Nishikawa et al., 1994) . Molecular determinants of this phenotype are not known, but likely include activation of PI3-K/Akt pathway and reduced expression of cyclin-kinase inhibitor, p27 (Narita et al., 2002) . Aberrant EGFRvIII receptor trafficking and degradation in the endosomal compartment has been implicated in sustained activation and signaling through the truncated receptor (Mineo et al., 1999) .
Recent studies (Smart et al., 1995; Mineo et al., 1999) have shown that a variety of cell surface receptors, including EGFR, as well as intracellular signaling molecules are concentrated in specialized plasma membrane domains known as caveolae. Caveolae are 50-100 nm vesicular organelles involved in a number of essential cellular functions, including signal transduction, protocytosis, lipid metabolism, cellular growth control and apoptotic cell death (Anderson, 1998) . Caveolin, a 21-24 kDa integral caveolae protein, functions as a scaffolding matrix to organize and concentrate caveolin-interacting signaling molecules within caveolae membranes (Shaul and Anderson, 1998) . It has been suggested that caveolin-1, which maps to a fragile site on chromosome 7 and is often deleted in human cancers, may have a tumor suppressor activity (Engelman et al., 1998a, b; Razani et al., 2001) . Antisense targeted downregulation of caveolin-1 in NH3T3 cells resulted in oncogenic transformation, anchorage-independent growth, p42/44 MAP kinase cascade activation and increased cell tumorigenicity in nude mice .
The caveolin-binding motif within the kinase domain of EGFR mediates the interaction of EGFR with caveolin-1 or -3 . EGFR rapidly moves out of caveolae domain in response to EGF (Mineo et al., 1999) . The expression of various mutated forms of EGFR, including EGFRvIII, disrupts receptor internalization and trafficking from caveolae (Mineo et al., 1999) . This paper presents evidence that the expression of caveolin-1 is increased in both glioblastoma cell lines and tumors. Moreover, the inhibition of EGFR and/or EGFRvIII tyrosine phosphorylation is shown to increase receptor association with caveolae. This phosphorylation-regulated sequestration of EGFR might be beneficial in arresting constitutive or ligand-induced signaling through EGFR that is responsible for cell transformation.
Results

Glioblastoma cell growth in a semi-solid agar
Human glioblastoma cell lines U87MG and U87MG-EGFRvIII stably express EGFR and EGFRvIII, respectively (Zhang et al., 2003) . The colonies formed in a semi-solid agar by U87MG ( Figure 1a ) were smaller and better delineated compared to those formed by U87MG-EGFRvIII cells (Figure 1c) . A continuous presence of the tyrosine kinase inhibitor, AG1478
(1 mM) in the cell media reduced both number and size of colonies formed by either U87MG (Figure 1b ) or U87MG-EGFRvIII cells (Figure 1d ).
Caveolin-1 is upregulated in glioblastoma cells and tumors
Since aberrant trafficking of EGFRvIII has been implicated in increased tumorigenicity of U87MG-EGFRvIII cells (Nishikawa et al., 1994) , the expression of caveolins in primary fetal human astrocytes (FHA), U87MG and U87MG-EGFRvIII cells was examined. Both RT-PCR (Figure 2a ) and Q-PCR (Figure 2b ) analyses demonstrated that caveolin-1 mRNA expression was higher in glioblastoma cell lines compared to FHA (Figure 2a, b) . Caveolin-1 mRNA expression was upregulated in U87MG-EGFRvIII compared to U87MG cells (Figure 2a, b) . In contrast, caveolin-2 (Figure 2a , b) and caveolin-3 ( Figure 2a ) mRNA expression was higher in FHA compared to glioblastoma cell lines. Caveolin-1 protein expression determined by Western blotting was upregulated (two-fold) in U87MG-EGFRvIII compared to U87MG cells ( Figure 2c ).
Caveolin-1 mRNA expression was examined in tissue samples of surgically removed GBM and compared to that in histopathologically nonmalignant brain lesions by Q-PCR ( Figure 3 ). All six GBM resections examined exhibited higher (ranging from 21-to 321-fold) caveolin-1 mRNA expression compared to two control (nonmalignant) brain samples ( Figure 3) . Coincidentally, GBM tissue #5 that showed the highest caveolin-1 expression (Figure 3 ) was also the only tissue that expressed EGFRvIII (data not shown). 
EGFR but not EGFRvIII colocalizes with caveolin-1 in glioblastoma cells
The colocalization of EGFR and EGFRvIII with lipid rafts and caveolin-1 in U87MG and U87MG-EGFRvIII, respectively, was examined by immunocytochemistry and confocal microscopy. Lipid rafts were visualized using FITC-labeled cholera toxin subunit B, which binds GM1 ganglioside, a lipid component highly abundant in lipid rafts (Harder et al., 1998) . Lipid rafts were densely distributed in plasma membranes of both U87MG and U87MG-EGFRvIII cells (Figure 4a, d ).
Immunoreactive EGFR was predominantly located in plasma membranes of U87MG cells ( Figure 4b ) and almost entirely colocalized with lipid rafts (Figure 4c ). In contrast, immunostaining for EGFRvIII revealed a predominantly cytoplasmic localization of the receptor in U87MG-EGFRvIII cells (Figure 4e ) with only minimal colocalization with lipid rafts (Figure 4f ). Exposure of U87MG cells to the cholesterol-depleting agent, methyl-b cyclodextrin (MBC; 1% for 30 min), previously shown to disrupt lipid rafts (Kanzaki and Pessin, 2002) , resulted in a discontinuous, patchy membrane staining (Figure 4g ). A redistribution of immunoreactive EGFR from the cell membrane into the cytoplasm ( Figure 4h ) and a loss of EGFR colocalization with the remaining lipid raft structures ( Figure 4i ) was observed in MBC-treated U87MG cells.
To determine whether EGFR colocalizes with caveolae, double immunocytochemistry for caveolin-1 and EGFR was performed ( Figure 5 ). In both U87MG (Figure 5a ) and U87MG-EGFRvIII (Figure 5d ), a punctate caveolin-1 staining decorated cell membranes, and, in particular, plasma membranes of cell processes Asterisks indicate a significant difference (Po0.01; ANOVA) from FHA. Number sign indicates a significant difference (Po0.01; ANOVA) between U87MG and U87MG-EGFRvIII cells Figure 3 Expression of caveolin-1 mRNA in surgically removed GBM and nonmalignant human brain tissue (Con) determined by Q-PCR. Caveolin-1 mRNA expression was determined in six samples of human GBM (designated 1-6) and two samples of nonmalignant human brain lesions as described in Materials and methods. b-Actin was used as an internal control. Each bar represents fold increase in caveolin-1 mRNA abundance in separate GBM tumor tissue (average of 2 Q-PCR determinations in each tumor sample) compared to the averaged value (normalized to 1) from nonmalignant brains EGFR and caveolin interactions A Abulrob et al ( Figure 5f -inset); some perinuclear staining was also observed (Figure 5a ). Preincubation of caveolin-1 antibody with the blocking peptide completely eliminated fluorescent staining (data not shown).
EGFR immunoreactivity (Figure 5b , c) superimposed with that of caveolin-1 in U87MG cells. The full-length EGFR has been previously reported to localize to caveolae (Smart et al., 1995) . In contrast, immunostaining for EGFRvIII in U87MG-EGFRvIII cells was predominantly cytoplasmic (Figure 5e ) without significant overlap with that for caveolin-1 (Figure 5f ).
Association of EGFR with caveolae is phosphorylationdependent
The effect of EGFR phosphorylation state on its association with caveolin peptides was examined. Exposure of U87MG to 100 ng/ml EGF for 10 min induced tyrosine phosphorylation of EGFR ( Figure 6a) ; the effect was blocked in cells pretreated with the tyrosine kinase inhibitor, AG1478 (Figure 6a ). Lipid raft disrupting MBC induced a ligand-independent tyrosine phosphorylation of EGFR (Figure 6a ), as previously reported (Chen and Resh, 2002) . EGFRvIII in U87MG-EGFRvIII cells was constitutively phosphorylated ( Figure 6a ) and its phosphorylation levels were not affected by either EGF or MBC (Figure 6a ), but were reduced by the tyrosine kinase inhibitor, AG1478 (Figure 6a ).
The effect of the EGFR phosphorylation state on its interaction with caveolin-1 or -2 was determined by the receptor binding to streptavidin beads precoated with caveolin-1 or -2 scaffolding domain peptides. Both caveolin-1-and caveolin-2-bound fractions of control U87MG cells displayed intense EGFR immunoreactivity (Figure 6b ). Binding was reduced in cells exposed to 100 ng/ml of EGF for 10 min (Figure 6b ). The tyrosine kinase inhibitor, AG1478, reversed the effect of EGF on EGFR binding to caveolin-1-, but not caveolin-2 scaffolding domain (Figure 6b ) in U87MG cells. In contrast, only minimal binding of EGFRvIII to caveolin-1 scaffolding domain peptide, which was not Figure 4 Colocalization of lipid rafts with either EGFR (a-c) or EGFRvIII (d-f) in U87MG or U87MG-EGFRvIII cells, respectively. Cells were prepared, fixed, immunostained, and visualized using confocal microscopy as described in Materials and methods. Lipid rafts (green fluorescence) (a, d and g) are stained with the FITC-cholera toxin B-subunit, while EGFR (b, h) (red fluorescence) and EGFRvIII (e) were immunostained using selective antibodies. Overlay (colocalization) images are shown in (c) and (f) for U87MG and U87MG-EGFRvIII cells, respectively. The effect of 1% methyl-b cyclodextrin (MBC) on lipid raft staining (g), EGFR immunostaining (h) and their colocalization in U87MG cells were also shown. Images are representative of at least four separate experiments yielding similar results
EGFR and caveolin interactions
A Abulrob et al affected by EGF, was observed in U87MG-EGFRvIII cells (Figure 6b ). However, in U87MG-EGFRvIII cells exposed to AG1478, the EGFRvIII binding to caveolin-1 scaffolding domain was markedly increased (Figure 6b ). These in vitro binding data suggested that EGFR association with caveolin-1 is disrupted upon constitutive or ligand-induced receptor phosphorylation.
To examine whether phosphorylation affects EGFR association with caveolin-1 in cells in vivo, colocalization studies were performed in intact cells exposed to AG1478 (Figure 7) . In U87MG cells exposed to 100 ng/ml EGF for 10 min, reduced colocalization of EGFR and caveolin-1 (Figure 7d To corroborate in vivo immunocytochemical studies, cells exposed to the same experimental treatments were subjected to fractionation under detergent-free conditions (Smart et al., 1995) to isolate caveolae. Caveolin-1 and EGFR or EGFRvIII were then immunodetected in various cellular fractions by Western blot. In both U87MG and U87MG-EGFRvIII cells, caveolin-1 expression was highly enriched in fractions 2 and 3 of the second Optiprep gradient ( Figure 8a ); these fractions were pooled and considered caveolae membranes. Cytosolic fraction (CS), plasma membrane fraction (PM) and noncaveolae membrane fraction (NCM) were analysed in parallel. In serum-starved U87MG cells, EGFR was enriched in CM fraction, but was also detected in other cellular fractions ( Figure 8b ). After exposure to EGF for 10 min, EGFR immunoreactivity disappeared from caveolae and plasma membrane fractions and was abundant in the cytosolic fraction ( Figure 8b ). Pretreatment with AG1478 prior to EGF addition prevented EGFR translocation from caveolae fraction into the cytosol (Figure 8b ). In contrast, in U87MG-EGFRvIII cells, EGFRvIII was predominantly localized in cytosol ( Figure 8b ) and was not detected in either plasma membrane or caveolae fraction ( Figure 8b ). Exposure of U87MG-EGFRvIII cells to EGF peptide did not alter the distribution of EGFRvIII ( Figure 8b) ; however, treatment with AG1478 resulted in a loss of EGFRvIII from cytosolic fraction and its appearance in both caveolae and plasma membrane fractions ( Figure 8b ).
Effect of AG1478 on caveolin-1 expression
To explore whether AG1478 affects the expression of caveolin-1, cells were exposed to the same concentrations of AG1478 used in binding and colocalization studies for either 30 min or 24 h. A 30-min exposure to AG1478 did not affect levels of caveolin-1 mRNA in 
Discussion
This study provides evidence to support the role of caveolae in EGFR sequestration in human glioblastoma cells. The migration of EGFR from caveolae is induced by both ligand-dependent and ligand-independent tyrosine phosphorylation of the receptor. Moreover, EGFR dissociation from caveolae appears to be associated with the more invasive phenotype of glioblastoma cells. These conclusions are supported by the following observations: (a) caveolin-1 expression positively correlates with the degree of glial cells transformation; in contrast, caveolin-2 and -3, expressed in primary astrocytes, are downregulated in glioblastoma cells; (b) caveolin-1 mRNA is more abundant in glioblastoma tumor tissues compared to nonmalignant brain tissues; (c) EGFR colocalized with lipid rafts and caveolin-1 in both caveolae fraction and intact U87MG cells and this association was rapidly disrupted by the ligand (EGF)-mediated phosphorylation of the receptor; (d) constitutively phosphorylated and ligand-independent EGFRvIII did not colocalize with either lipid rafts or caveolin-1 in U87MG-EGFRvIII cells, while the tyrosine kinase inhibitor AG1478 increased the association of EGFRvIII with caveolin-1. Furthermore, the disruption of caveolae vesicles resulted in both enhanced phosphorylation and cytoplasmic redistribution of EGFR. Since the caveolin-1 binding to EGFR has been shown to negatively regulate EGFR tyrosine and serine/ threonine kinase activities , and the suppression of EGFR tyrosine kinase attenuates 'malignant' properties of transformed cells (Han et al., 1996) , we conclude that the phosphorylation-dependent EGFR Figure 6 Effects of EGFR or EGFRvIII tyrosine phosphorylation on their interactions with caveolins. (a) Tyrosine phosphorylation of EFGR and EGFRvIII in U87MG or U87MG-EGFRvIII cells preincubated with 1 mM AG1478 or 10 mM methyl-b cyclodextrin (MBC) for 30 min and then exposed to 100 ng/ml EGF for 10 min. U87MG or U87MG-EGFRvIII cell lysates were immunoprecipitated with anti-EGFR or anti-EGFRvIII antibodies, respectively, followed by immunoblotting with antiphosphotyrosine antibody, as described in Materials and methods. (b, c) EGFR or EGFRvIII binding to caveolin-1 or -2 scaffolding domain peptides. U87MG (a) or U87MG-EGFRvIII (b) cells were treated with 1 mM AG1478 and 100 ng/ml EGF alone or in combination and their lysates were then incubated with streptavidin beads coated with biotinylated caveolin-1 (full bars) or caveolin-2 (empty bars) scaffolding domain peptides as described in Materials and methods, and probed on a Western blot with antibodies against EGFR (b) and EGFRvIII (c), respectively. Bar graphs are densitometry quantification of bands (average7s.d.) from three separate experiments. Asterisks indicate significant difference (ANOVA, Po0.05) from no treatment; number signs indicate significant difference (ANOVA, Po0.05) from EGF alone EGFR and caveolin interactions A Abulrob et al receptor trafficking in and out of caveolae is an important process involved in EGFR-dependent cellular transformation. Caveolae assemble a spectrum of signaling molecules in discrete plasma membrane subdomains, providing proximity for their interaction and facilitating cross-talk between different signaling pathways Schlegel et al., 2000) . The interactions of various signaling molecules including H-Ras, heterotrimeric Gproteins, EGFR, protein kinase C (PKC), Src-family tyrosine kinases, and nitric oxide synthase (NOS) isoforms with caveolin-1 results in their inactivation (Lisanti et al., 1994; Couet et al., 1997; Okamoto et al., 1998) . Since many of these signaling molecules can cause cellular transformation when constitutively activated, it was suggested that caveolin-1 has a transformation suppressor activity. Downregulation or absence of caveolin-1 expression has been observed in various tumor tissues and cell lines transformed by oncogenes (Racine et al., 1999; Bender et al., 2000; Wiechen et al., 2001) . However, increased expression of caveolin-1 has also been associated with development of various tumors including prostate and breast cancers (Thompson, 1998; Yang et al., 1998; Kato et al., 2002) . A recent study (Cameron et al., 2002) reported that the caveolin-1 mRNA and protein were expressed at variable levels in Figure 7 Effects of EGFR or EGFRvIII tyrosine phosphorylation on their interactions with caveolin-1 determined by immunocytochemistry. (a-f) Caveolin-1 (red fluorescence) and EGFR (green fluorescence) immunostaining in control U87MG cells (a-c) and cells subjected to 100 ng/ml EGF for 10 min (d-f) and their colocalization (c, f). (g-l) Caveolin-1 (red fluorescence) and EGFRvIII (green fluorescence) immunostaining in control U87MG-EGFRvIII cells (g-i) and cells subjected to 1 mM AG1478 for 30 min (j-l) and their colocalization (i, l). Immunocytochemistry and confocal microscopy were performed as described in Materials and methods. Images are representative of at least four separate experiments yielding similar results different types of glioma cells; however, no comparisons with primary human astrocytes were previously made. Forget et al. (2002) recently reported that immunodetected caveolin-1 protein expression in astrocytic tumors of various grades was not significantly different from that in the normal brain. In glioblastoma cells examined in this study, increases in caveolin-1 mRNA and protein expression were both correlated with the more transformed cellular phenotype, and consistently detected in glioblastoma tumors, suggesting a role for caveolin-1 in glial tumorigenesis.
Whereas caveolin-1 can form caveolae by homopolymerization, both caveolin-2 and -3 need to heterodimerize with caveolin-1 to form caveolae (Scherer et al., 1997) . However, specific roles of caveolin-2 and -3 in modulating functional properties of caveolae are not known. In the brain, caveolin-3 is selectively expressed in astroglial cells (Ikezu et al., 1998) and upregulated in reactive astrocytes (Nishiyama et al., 1999) . In addition to caveolin-1 upregulation, astroglial cell transformation in this study was associated with both caveolin-2 downregulation and almost complete loss of caveolin-3. No prior analyses of caveolin-2 and -3 expression in glioma cells and tissues have been published. We propose that the combination of caveolin-1 upregulation and astrocyte-specific caveolin-3 disappearance may be a specific 'signature' of transformed glial cells. Recent analyses of differential protein expression maps of primary human astrocytes and U87MG cells suggested that regulatory checkpoints of transcription, translation, protein processing, and extracellular matrix adhesion and hydrolysis are also significantly altered in glioblastoma cells and may contribute to their transformed phenotype (Zhang et al., 2003) .
The EGFR gene is amplified in 40% of glioblastomas; these tumors also show additional genomic rearrangements of EGFR gene, the most common of which is type III mutation (Nishikawa et al., 1994) . The truncated receptor shows constitutive tyrosine kinase activity 
EGFR and caveolin interactions
A Abulrob et al (Nishikawa et al., 1994; Voldborg et al., 1997) and aberrant receptor signaling and processing (Nagane et al., 2001) . Therapeutic strategies that target EGFR, including antibodies (Jungbluth et al., 2003) and immunoliposomes (Mamot et al., 2003) , as well as small-molecule agents that inhibit the EGFR-tyrosine kinase, have been developed for treatment of cancers characterized by EGFR amplification (Mischel and Cloughesy, 2003) . A limited success (increased median survival) has been reported in a clinical study that tested iodinated anti-EGFR monoclonal antibody 425 as adjuvant therapy for high-grade astrocytomas and glioblastomas (Emrich et al., 2002) . However, difficulties in delivery of antibody-based treatments to the brain underscore the need for alternative and/or complementary strategies to attenuate aberrant signaling through the amplified EGFR. The evidence presented in this manuscript suggests that EGFR association with lipid raft and caveolae domains regulates receptor sequestration, trafficking and signaling in glioblastoma cells. The role of caveolae in sequestration and modulation of signaling through EGFR has been studied in various other cells types with controversial results. In quiescent fibroblasts, EGFR has been detected in caveolae and rapidly moves out of these membrane domains in response to EGF (Mineo et al., 1999) . Similarly, EGFR has been shown to directly interact with the caveolin-1 scaffolding domain via a caveolin-binding motif within the receptor kinase domain in A431 cells; this interaction resulted in the inhibition of EGFR tyrosine and serine/threonine kinase activities . Others reported a random distribution of EGFR in plasma membranes in various cancer cells with only minimal colocalization with caveolae (Ringerike et al., 2002) . In general, migration from caveolae into other plasma membrane compartments and subsequent endocytosis via clathrincoated pits are considered initial steps in EGFR internalization and signaling (Stang et al., 2000) . Impaired exit from caveolae of some mutant EGFRs has been linked to aberrant signaling and cellular transformation in fibroblasts (Mineo et al., 1999) . Therefore, caveolin-1 can influence signaling through EGFR by either direct interaction with EGFR tyrosine kinase (Engelman et al., 1998a, b; Couet et al., 1997) or by sequestration of multiple components of EGFR signaling cascade(s) including initial events of Ras/Raf-1, Mek and MAP kinase recruitment (Mineo et al., 1996; Engelman et al., 1998a, b) . The interactions of caveolin-1 with EGFR and their consequences on cell transformation have not been studied in cells and tumors of astrocytic origin.
In U87MG cells, EGFR was found to colocalize with caveolin-1 in both caveolae-enriched membrane fractions and intact cells under resting conditions and 'exits' caveolae after tyrosine phosphorylation induced by EGF. In contrast, ligand-independent and constitutively phosphorylated EGFRvIII did not localize to either lipid raft or caveolae domains and was detected almost exclusively in cytosolic fraction; when the constitutive phosphorylation of the receptor was reduced by the tyrosine kinase inhibitor, AG1478, the mutant receptor became associated with caveolin-1 and caveolae membrane fraction. This agrees with Ekstrand et al. (1995) , who reported that EGFRvIII was not localized to the plasma membrane. Most importantly, the inhibition of EGFR tyrosine kinase activity resulted in both increased localization of EGFR with caveolae and attenuation of transformed cellular phenotype. Furthermore, EGFR activation can increase caveolin-1 phosphorylation (Kim et al., 2000) ; caveolin-1 is a major v-Src tyrosine phosphorylated protein in Rous sarcoma virus-induced cell transformation (Glenney and Soppet, 1992) . This implies that strategies that maintain or enhance EGFR 'capture' by caveolae may be used in conjunction with direct EGFR receptor targeting to attenuate aberrant signaling and cellular transformation.
A new molecular complex consisting of the Casitas B-lineage (Cbl) proteins and adaptor protein SETA/CIN85/Ruk, associated with tumorigenic transformation of astrocytes, has been implicated in ubiquitination and internalization of tyrosine kinase receptors, including EGFR (Schmidt et al., 2003) . Interestingly, AG1478 causes the dissociation of SETA and Cbi proteins with concomitant attenuation of receptor internalization (Schmidt et al., 2003) , suggesting an alternative mechanism by which AG1478 could regulate EGFR association with caveolae. Interestingly, longer treatment of U87MG cells with AG1478 resulted in the upregulation of caveolin-1, suggesting a positive feedback loop. Therefore, in addition to direct inhibition of the tyrosine kinase-mediated signaling and possible effects on other kinase and nonkinase targets, AG1478 can suppress tumorigenicity of U87MG cells by increasing cellular capacity to sequester EGFR in caveolae.
Modulation of the number and functionality of lipid rafts and caveolae can be achieved with cholesterolmodulating agents. In this study, the cholesteroldepleting agent, MBC, disrupted lipid rafts and induced EGFR phosphorylation. Chen and Resh (2002) also demonstrated a ligand-independent activation of EGFR in COS-1 cells. Although it is unclear whether MBC induces EGFR phosphorylation directly or indirectly, through changes of biophysical properties of the plasma membrane, a recent study suggested that the introduction of cholesterol into a liposome membrane resulted in decrease of reconstituted EGFR kinase activity (Ge et al., 2001) . Similarly, cholesterol-modulating statins, also known to disrupt caveolae, have potent antitumor effects (Jakobisiak and Golab, 2003) . Therefore, modulation of EGFR sequestration in caveolae and EGFR signaling inhibition could feasibly be achieved by agents that affect cellular cholesterol levels.
Evidence presented in this study suggests that low phosphorylation states of EGFR or EGFRvIII are accompanied by increased localization of the receptor in caveolae and attenuation of the transformed glioblastoma cell phenotype. Therefore, strategies that support or induce EGFR association with caveolae may be beneficial in suppressing aberrant signaling through the receptor in glioblastoma cells and tumors.
Materials and methods
Materials
Cell culture plastics were obtained from Becton Dickinson. Dulbecco's modified Eagle's medium (DMEM), fetal bovine serum (FBS), penicillin G, streptomycin, Trizol RNA extraction reagent, Moloney murine leukemia virus-RT (MMLV-rt), DTT, 100 bp DNA ladder, and dNTPs were purchased from Invitrogen (Burlington, ON, Canada); oligo(dT) 12-18 primers purchased from Cortec (Kingston, ON, Canada); Agarose ultra-pure grade from Multicell; Taq DNA polymerase and avian myeloblastosis virus reverse transcriptase purchased from Promega (Madison, WI, USA); SYBR green PCR Core Reagents from Applied Biosystems (Foster City, CA, USA). Recombinant human EGF peptide was from Peprotech (Rocky Hill, NJ, USA). AG1478 and anticholera toxin subunit B antibody were purchased from Calbiochem (San Diego, CA, USA). Sepharose A was purchased from Amersham Pharmacia (Quebec, QC, Canada). Protein G beads, polyclonal anticaveolin-1, polyclonal anti-EGFR antibodies and caveolin-1 blocking peptide were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Monoclonal anti-EGFR type III was purchased from Zymed (Markham, ON, Canada). Antiphosphotyrosine clone 4G10 was purchased from Upstate Biotechnology (Waltham, MA, USA). Alexa-568 anti-rabbit secondary antibody was purchased from Molecular Probes (Eugene, OR, USA). Optiprep was purchased from Accurate Chemical and Scientific Corp. All other chemicals were from Sigma (St Louis, MO, USA).
Cell culture
The human glioma cell line U87MG expressing wild-type EGFR, and its subline expressing EGFR with an in-frame deletion of 801 bp (exons 2-7) (EGFRvIII) (Nishikawa et al., 1994) were kindly provided by Professor W Cavenee, Ludwig Institute for Cancer Research, University of California, San Diego. Primary fetal (10-18 weeks of gestation) human astrocyte (FHA) cultures were generously provided by Dr J Antel (Montreal Neurological Institute, Montreal, QC, Canada) . These cultures were prepared using previously described procedures (Yong, 1992) . All cells were grown in DMEM supplemented with 2 mM glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin and 10% heat-inactivated FBS (Hyclone; Logan, UT, USA) in an atmosphere of 5% CO 2 / 95% air at 371C. Frozen surgical tumor samples were obtained from the Brain Tumor Bank of the Ottawa General Hospital. Use of human cells and materials for this study was approved from the Institutional Ethics Boards of the National Research Council, Montreal Neurological Institute and Ottawa General Hospital.
Subcellular fractionation and isolation of low-density caveolae membranes
Detergent-free method described by Smart et al. (1995) was used to isolate caveolae. All steps were carried out at 41C and all buffers were supplemented with the protease inhibitor cocktail (Sigma). A plasma membrane fraction was prepared from eight 175 cm 2 tissue culture dishes of confluent control cells or cells exposed to EGF (100 ng/ml) for 10 min or AG1478 (1 mM, 30 min) alone or followed by EGF (100 ng/ml) for 10 min. Each dish was washed twice with 10 ml of buffer A (0.25 M sucrose, 1 mM EDTA, and 20 mM Tricine, pH 7.8). Cells were collected by scraping in 5 ml of buffer A, pelleted by centrifugation at 1400 g for 5 min (Beckman J-68; 3000 r.p.m.), resuspended in 1 ml of buffer A, and homogenized in a Teflon glass homogenizer by 20 up/down strokes. Homogenized cells were centrifuged twice (with repeated homogenation step inbetween) at 1000 g for 10 min (Eppendorf Centrifuge 5415C; 3000 r.p.m.). Two resulting postnuclear supernatants (PNS) were pooled, overlaid onto 23 ml of 30% Percoll solution in buffer A and ultracentrifuged at 83 000 g (30 000 r.p.m.) for 30 min in a Beckman 60Ti centrifuge. The plasma membrane (PM) fraction (a visible band 5-6 cm from the bottom of the tube) was collected, adjusted to 2 ml with buffer A and sonicated 6 times at 50 J/W/s (Fisher Sonic Dismembrator 300). The remaining fraction, considered cytosol (CS) was collected and stored at 41C for Western blot analyses. The sonicated membrane fraction was then mixed with 50% Optiprep in buffer B (0.25 M sucrose, 6 mM EDTA, and 120 mM Tricine, pH 7.8) to achieve a final Optiprep concentration of 23%. The entire solution was placed at the bottom of the Beckman SW41Ti tube, overlaid with a linear 20-10% Optiprep gradient, and centrifuged at 52 000 g (18 000 r.p.m.) for 90 min using SW41Ti (Beckman Instruments). The bottom 2 ml was designated noncaveolae membrane (NCM). The top 5 ml of the gradient was collected and mixed with 50% Optiprep in buffer B, placed on the bottom of a SW41Ti tube, overlaid with 2 ml of 5% Optiprep in buffer A, and centrifuged at 52 000 g for 90 min. An opaque band located just above the 50% interface represents caveolae membrane (CM) fraction. The gradient is then divided into 10 1-ml fractions, total protein in each fraction was precipitated by 10% trichloroacetic acid, washed 3 times in acetone, airdried, dissolved in Laemmeli buffer, separated using 15% SDS-PAGE and probed for the presence of caveolin-1 using Western blot. Fractions 2 and 3 demonstrated high caveolin-1 immunoreactivity and in subsequent experiments were pooled and designated the caveolae membrane (CM) fraction.
Cell growth in a semi-solid agar
Anchorage-independent growth of U87MG cells expressing EGFR or EGFRvIII was examined in a semi-solid agar. DMEM containing 10% FBS was warmed to 481C and diluted with Bacto-Agar to make a 0.6% (w/v) agar solution; 3 ml of the solution was poured into 60 mm plates and allowed to solidify for 15 min. A volume of 2 ml of 0.3% agar solution (prepared as above) containing 25 000 cells/dish was then poured over the bottom agar layer. Cells were plated in duplicate and grown in 5% CO 2 atmosphere at 371C in the absence or presence of 1 mM AG1478. Cell media were changed every second day and the formation of colonies was assessed after 3 weeks.
Reverse transcriptase-polymerase chain reaction
Total RNA was isolated from cultured cells using Trizol reagent. To synthesize first-strand cDNA, 0.5 mg RNA was reverse transcribed using 200 U of Moloney murine leukemia virus-reverse transcriptase (RT), 10 pmol of oligo dT, 10 mM DTT, and 1 mM dNTPs in a total volume of 20 ml. cDNA was subjected to PCR Genetic Research Instrumentation Ltd.) to amplify EGFR, EGFRvIII, caveolin-1, -2, and -3 genes. Primer sequences for these genes (Table 1) were designed using Oligot 4.0 primer design software according to published sequences (GeneBank), and synthesized by Alpha DNA Ltd (Montreal, Canada). Amplification of human EGFR and EGFRvIII was achieved in a final volume of 25 ml using 1 U of Taq DNA polymerase, 1 Â PCR buffer, 1.5 mM MgCl 2 , 0.2 mM dNTPs and 0.2 mM of each primer. The PCR reaction was carried out as follows: initial denaturation at 941C for 2 min, followed by denaturation at 941C for 45 s, annealing at 601C for 45 s, and polymerization at 721C for 90 s. The reaction was carried out over 30 cycles and completed by an extended polymerization at 721C for 10 min (Worm et al., 1998) . PCR amplification of human caveolin-1, -2 and -3 genes was as follows: initial denaturation at 951C for 2 min, followed by denaturation at 941C for 45 s, annealing at 551C for 45 s, and polymerization at 721C for 45 s, for a total of 25-30 cycles. The housekeeping gene, a-actin, was amplified from each sample using specific primers (Table 1 ). All experiments were performed using conditions optimized for linear amplification. To separate the PCR products, 10 ml of each PCR reaction was subjected to electrophoresis on a 1.2% agarose gel (0.5 Â TBE buffer) and stained with ethidium bromide (0.5 mg/ml). The fluorescent bands were imaged under UV light, and analysed using Kodak gel documentation image station 1000 and Kodak 1D image analysis software from Perkin-Elmer (Woodbridge, ON, Canada). Negative controls where either the RT enzyme or cDNA product were omitted were run in parallel. All primer sets used yielded amplified products of expected size (Table 1) . Sequencing analysis, carried out using an Applied Biosystems 373A automated DNA sequencer and the BigDye Terminator Cycle Sequencing kit (Perkin-Elmer, Applied Biosystems), confirmed the identity of amplified PCR products.
Real-time PCR
Total RNA was primed with oligo(dT) 12-18 primers and reverse transcribed with 1-3 U avian myeloblastosis virus RT. Control reactions lacking the enzyme were run in parallel to check for genomic contamination. Primers for caveolin genes and b-actin (Table 1) were designed using Primer Express 2.0 program. Real-time, quantitative PCR (Q-PCR) was carried out with SYBR s Green PCR Core Reagents Kit using the ABI Prism 7700 Sequence Detector System (PerkinElmer). For each amplicon, the amount of target and endogenous reference (b-actin) was determined from a standard curve generated by serial dilutions ranging from 1 : 10 to 1 : 1000. Complementary DNA representing 50 ng of mRNA was subjected to 40 cycles of PCR amplification using SYBR green reagents. Prior to amplification, samples were incubated at 501C for 2 min (AmpErase UNG Incubation), 951C for 15 min (AmpliTaq Gold activation). Each amplification cycle consisted of denaturation for 15 s at 951C, annealing/extension for 1 min at 601C. To confirm that the expected product was generated and to distinguish specific from nonspecific products and primer-dimers, a melting-curve analysis was performed after amplification by maintaining the temperature at 701C for 30 s, followed by a gradual increase in temperature to 981C at a rate of 0.11C/s, with the signal acquisition mode set at step-acquisition mode. For each sample, the formation of PCR products was monitored fluorimetrically based on the incorporation of SYBR Green.
The standard curve was amplified in triplicate during each experiment, and the amount of target gene was normalized to the endogenous reference. The relative amounts of caveolin and b-actin were determined from the calibration curve. The PCR efficacy was close to 100% for caveolin-1, -2, and b-actin. Each measurement was performed in duplicate. The intra-assay CV was o5 and o9% for caveolin-1 and -2, respectively. The sequence identity of amplified genes with published sequences of human genes (BLAST, NCBI) was 495%.
Gel electrophoresis and Western blot
Cells were cultured to 80% confluence, washed twice with HBSS and then lysed in loading buffer. Total protein concentration in cell lysates was measured using Bio-Rad protein assay kit. Alternatively, various cellular fractions obtained by subcellular fractionation were used for Western blot. An equal amount of protein from each lysate (10 mg) or subcellular fraction (5 mg) was separated by SDS-PAGE electrophoresis. Separated proteins were then transferred to a PVDF membrane (Immobilon-P membrane, Millipore) in 25 mM Tris-HCl, 192 mM glycine, and 25% methanol. The membranes were blocked in 5% skim milk in TBST (10 mM Tris-HCl, pH 8.5, 150 mM NaCl, 0.1% Tween-20) for 1 h at 251C. The membranes were then probed with polyclonal anticaveolin-1 (1 : 500; Santa Cruz Biotechnology, Santa Cruz, CA, USA) or polyclonal anti-EGFR (1 : 500; Santa Cruz Biotechnology) or monoclonal anti-EGFRvIII (1 : 1000; Zymed, Markham, ON, Canada) antibody for 1 h at room temperature. Membranes were washed in TBST (3 Â 15 min), incubated with the corresponding HRP-conjugated secondary antibody diluted 1 : 5000 in TBST/5% milk for 1 h, and washed in TBST (6 Â 10 min). Immunoreactive protein was detected using ECL-Plus Western blotting detection system (Amersham Pharmacia Biotech, Quebec, QC, Canada).
Immunocytochemistry
Fluorescent staining of lipid raft domains was performed using cholera toxin patching method as described (Janes et al., 1999) . Cells were first incubated with 10 mg/ml FITC-labeled cholera toxin subunit B (Sigma) in HBSS containing 0.1% BSA for 30 min on ice. To cross-link lipid rafts (patching), cells were subsequently incubated with anticholera toxin subunit B antibody (Calbiochem, San Diego, CA, USA) (1 : 250 in HBSS/0.1%BSA) for 30 min on ice and then for 20 min at 371C. Cells were then fixed with 4% paraformaldehyde, and immunostained for EGFR or EGFRvIII as described below.
Colocalization of EGFR and EGFRvIII with lipid rafts or caveolin-1 in U87MG or U87MG-EGFRvIII cells, respectively, was studied by double immunocytochemistry. Cells were initially fixed with 4% paraformaldehyde for 10 min 
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EGFR and caveolin interactions A Abulrob et al followed by permeabilization step using 0.1% Triton X-100 for 10 min and a subsequent blocking of nonspecific sites using 4% goat serum for 1 h. Cells were then incubated with anticaveolin-1 antibody (Santa Cruz Biotechnology; 1 : 100, 1 h, room temperature), washed, and then exposed to Alexa-568 labeled anti-rabbit IgG antibody (Molecular Probes; 1 : 500, 1 h). Slides were then exposed to 4% goat serum overnight. U87MG and U87MG-EGFRvIII cells were then exposed to the polyclonal anti-EGFR antibody (Santa Cruz Biotechnology; 1 : 100; 1 h, room temperature) and monoclonal antiEGFRvIII antibody (Zymed; 1 : 100; 1 h, room temperature), respectively. Visualization was undertaken using FITC-conjugated anti-rabbit and anti-mouse IgG antibodies to detect EGFR and EGFRvIII, respectively. The coverslips were then washed 5 Â times and mounted in fluorescent mounting medium (Dako Cytomation, Mississauga, ON, Canada). The specificity of caveolin-1 antibody was confirmed by preincubation with five-fold excess of the caveolin peptide in 500 ml of HBSS for 2 h at room temperature resulting in the absence of fluorescent staining. Primary antibodies were omitted in negative controls. No cross-reactivity was detected between the primary and noncorresponding secondary antibodies. Imaging of the slides was performed using Zeiss LSM 410 (Carl Zeiss, Thornwood, NY, USA) inverted laser scanning microscope (LSM) equipped with an Argon\Krypton ion laser and the Plan neofluar 63X, 1.3 NA oil immersion objective.
Peptide synthesis
Peptides corresponding to the putative scaffolding domains of caveolin-1 (amino acids residues 82-101; DGIW-KASFTTFTVTKYWFYR) and caveolin-2 (amino-acid residues 54-73; DKVWICSHALFEISKYVMYK) were synthesized in the Peptide Synthesis Core facility at NRC-IBS (Ottawa, ON, Canada), biotinylated, and purified (498%) by HPLC. Amino-acid sequence of synthesized peptides was confirmed by mass spectrometric analysis. Stock solutions of peptides (4 mM) were dissolved in DMSO and stored at À801C. The final concentration of DMSO was less than 0.5%.
EGFR phosphorylation and interaction with caveolin-1 U87MG or U87MG-EGFRvIII cells were grown to 80% confluence in 60-mm Petri dishes, serum-deprived for 16 h, and then exposed to the cholesterol-binding drug, methyl b-cyclodextrin (10 mM) or to the EGFR tyrosine kinase inhibitor, AG1478 (1 mM) for 30 min at 371C. After treatments, some cultures were stimulated with EGF (100 ng/ml) for 10 min. Cells were immediately rinsed twice in HBSS at room temperature and lysed in 1 ml of ice-cold buffer containing 20 mM Tris-HCl, 1% Triton X-100, 150 mM NaCl, 5 mM EDTA and protease inhibitor cocktail with gentle rocking for 10 min at 41C. The samples were centrifuged at 41C for 30 min at 14 000 g. Supernatants were collected and protein content determined using Bio-Rad protein assay kit.
To detect EGFR phosphorylation, 500 mg of supernatant protein from U87MG or U87MG-EGFRvIII cells was incubated with 3 mg of either polyclonal anti-EGFR or monoclonal anti-EGFRvIII antibody, respectively, overnight at 41C while gently rocking. Immunobound lysates of U87MG and U87MG-EGFRvIII were then mixed with protein G beads (80 ml) or protein A sepharose slurry (50 ml), respectively, incubated for 2 h at 41C with gentle rocking, washed with icecold lysis buffer (2 Â 15 min) and subsequently with ice-cold HBSS (3 Â 15 min). The beads or slurry were boiled in Laemmeli buffer for 10 min to dissociate bound protein and centrifuged for 1 min at 14 000 g to collect immunoprecipitated protein. Immunoprecipitated protein samples were separated on 8% SDS gel and transferred to PVDF membranes. Membranes were probed with the antiphosphotyrosine antibody (Upstate Biotechnology, 1 : 500, 2 h) to detect phosphorylation of either EGFR or EGFRvIII. Protein G beads and protein-A sepharose alone served as negative controls.
To assess EGFR binding to caveolin scaffolding domains, 1 mm streptavidin coated iron-oxide beads (Sigma) were incubated with 10 mM of biotinylated caveolin-1 or -2 scaffolding domain peptides for 1 h at 41C. A measure of 500 mg of protein from cell lysates (prepared as above), was incubated with streptavidin beads coated with caveolin scaffolding domain peptides overnight at 41C. The beads were collected using Dynal magnetic particle concentrator MPC-1 (Lake Success, NY, USA) and washed extensively with HBSS. Bound proteins were dissolved in loading buffer, dissociated from the beads by boiling at 951C for 10 min, and beads were removed by Dynal magnetic particle concentrator MPC-1. Supernatants were collected and separated by SDS-PAGE; proteins were transferred onto PVDF membrane and probed with anti-EGFR antibody or anti-EGFRvIII antibody as described above. Streptavidin beads alone served as a negative control.
